Home » Contract Manufacturing

Contract Manufacturing

Print page

CONTRACT MANUFACTURING POSSIBILITIES:

  • procurement of raw materials
  • manufacture of bulk products
  • confection and packaging
  • stability studies
  • quality control and product release for sales

AVAILABLE PHARMACEUTICAL FORMS:

  • Solid forms of drugs (capsules, tablets, coated tablets, powders) including penicillin forms
  • Sterile forms of drugs (sterile powders and lyophilized powders for injection) including penicillin forms
  • Dermatological forms of drugs (gels and aerosols)
  • Insulins

FORMS OF PACKAGING:

  • Bottles (oral suspensions)
  • Blisters ALU /ALU; ALU/PCV; ALU / PVDC (capsule, tablets)
  • Vials
  • Tubes (gels)
  • Containers (pressure aerosols)
  • Insulin cartridges
Services

Modern production facilities and maintaining production processes in accordance with international standards guarantee quality of manufacturing. The integrated nature of our business allows us to offer production of finished formulations, active pharmaceutical ingredients and laboratory services.

Contract manufacturing services

Polfa Tarchomin S.A. provides contract manufacturing services. The manufacturing is realised in headquarters located in Warsaw in seven facilities and in one facility situated in Lodz. All facilities and infrastructure installed are in compliance with EU cGMP requirements At present our offer in respect to contract manufacturing includes:

Solid forms non-sterile
  • Tablets
  • Coated tablets (organic, sugar coating)
  • Hard gelatin capsules
  • Powders/ granules for oral suspension
Solid form sterile
  • Powders  for Injection/ infusion (vials)
  • Powders for Injection/ infusion lyophilizate, line  availability  2026
Semisolid forms non-sterile
  • Dermatological aerosols (pressure cans)
  • Topical gels (aluminum or PE tubes)
  • Ointments (aluminum or PE tubes)
Liquid forms not-sterile
  • Dermatological and biocidal solutions (bottles)
Liquid forms sterile
  • Insulin preparations (cartridges)
  • Glass ampoules
  • Glass vials, including  high-potent products,  line  availability  2026
  • Insulin preparations (cartridges)

 

Primary and secondary packing
  • Individual packing of above mentioned forms i.e. blisters, containers, bottles, ampules, cartridges and vials
  • Secondary and collective packaging: folding boxes, cartons in different sizes, colors and configurations
  • Serialisation and aggregation

 

API synthesis
  • Three lines for API synthesis;
  • Line for synthesis of cytostatics
  • Micronisation of substances
Other services
  • Chemical & microbiological analyses including release for circulation
  • Stability studies
  • Procurement & warehousing of starting and packaging materials
Estimated annual capacities:

Estimated annual capacities: 

  • Injectables - dry powders
  

between 2 M. (lyophilisation)  – 15 M. (filling) vials

 
  • Injectables - sterile solutions
  

10 M. (ampules);  6 M. (cartridges);  10 M. (vials).

 
  • Injectables - High-potent (up to OEB 5) parenteral dosage forms
  

between 0,6 M. (lyophilisation)  – 3 M. (filling) vials or PFS

 
  • Solid oral dosage forms
  

100 M. (tablets or capsules ); dry powders 0,5 M. bottles

 
  • Semisolid dosage forms
  

1 M. (gels or ointments ); 2 M. aerosol cans

 
 

  • Active pharmaceutical ingredients and Intermediates

 

  

approx. 15 batches

 

 

Contact

Contract Manufacturing Department

Phone. +48 512 000 770

e-mail:

aadaszkiewicz@polfa-tarchomin.com.pl

jlamecka@polfa-tarchomin.com.pl

Project co-financed with the participation of the domestic founds and EU Funds

Public Information Bulletin